Guo Jing, Sun Jian-Hua, Chen Lu, Geng Hao, Wu Xiao-Liang, Song Ya-Fang, Yang Guo-Hui, Shen Rong-Rong, Ding Min, Lu Jin, Liu Lian, Fang Xiang-Dong, Pei Li-Xia
Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
Department of Acupuncture-Moxibustion, Shuyang Hospital of TCM.
Zhongguo Zhen Jiu. 2021 Apr 12;41(4):365-70. doi: 10.13703/j.0255-2930.20200313-k0002.
To compare the curative effect on diarrhea-predominant irritable bowel syndrome (IBS-D) between acupuncture for regulating and strengthening spleen and pinaverium bromide, and explore the relevant mechanism of curative effect of acupuncture in view of polymorphism of 5-hydroxytryptamine transporter gene-linked polymorphic region (5-HTTLPR).
A total of 231 patients with IBS-D were randomized into an acupuncture group (154 cases) and a western medication group (77 cases) at the ratio of 2 to 1. In the acupuncture group, acupuncture was applied to acupoint regimen for regulating and strengthening spleen, i.e. Baihui (GV 20), Yintang (GV 29), Tianshu (ST 25), Shangjuxu (ST 37) and Zusanli (ST 36), etc. The treatment was given once every 2 days, 3 times a week. In the western medication group, pinaverium bromide was prescribed for oral administration, 50 mg each time, 3 times daily. The duration of treatment was 6 weeks in each group. Separately, before treatment, after treatment and in 3-month follow-up, the IBS symptom severity scale (IBS-SSS) and IBS quality of life scale (IBS-QOL) scores were adopted in assessment. After treatment, the curative effect and safety were compared between the two groups. Before treatment, 5-HTTLPR genotypes were determined in the patients.
After treatment and in follow-up, the total scores of IBS-SSS in the patients of the two groups were all reduced as compared with those before treatment (<0.01) and the scores in the acupuncture group were lower than those in the western medication group (<0.01). After treatment and in follow-up, the total scores of IBS-QOL in the two groups were all increased as compared with those before treatment (<0.01) and the score in the acupuncture group was higher than the western medication group in follow-up (<0.01). The total effective rate was 79.2% (122/154) in the acupuncture group, higher than 58.4% (45/77) in the western medication group (<0.01). There was no severe adverse reaction found in the two groups. The difference in the total score of IBS-SSS before and after treatment in the patients with LS and SS genotypes was greater than that in the patients with LL in the acupuncture group (<0.01). The difference in the total score of ISB-SSS before and after treatment in the patients with SS genotype was greater than that in the patients with LL in the western medication group (<0.01). The difference in the total score of IBS-SSS before and after treatment in the patients with LS and SS genotypes in the acupuncture group was greater than that in the patients with the same genotypes in the western medication group (<0.01).
Acupuncture for regulating and strengthening spleen achieves the more curative effect on IBS-D as compared with pinaverium bromide. The acupuncture regimen effectively relieves the clinical symptoms and improves the quality of life in patients as well as presents a satisfactory long-term effect and safety. The clinical curative effect of acupuncture is correlated with 5-HTTLPR polymorphism, in which, the curative effect of acupuncture may be more effective in the patients with LS and SS genotypes.
比较健脾调神针刺法与匹维溴铵治疗腹泻型肠易激综合征(IBS-D)的疗效,并从5-羟色胺转运体基因连锁多态性区域(5-HTTLPR)多态性角度探讨针刺疗效的相关机制。
将231例IBS-D患者按2∶1比例随机分为针刺组(154例)和西药组(77例)。针刺组采用健脾调神针刺法,针刺百会(GV 20)、印堂(GV 29)、天枢(ST 25)、上巨虚(ST 37)、足三里(ST 36)等穴位,每2日治疗1次,每周3次。西药组口服匹维溴铵,每次50mg,每日3次。两组疗程均为6周。分别于治疗前、治疗后及3个月随访时采用肠易激综合征症状严重程度量表(IBS-SSS)和肠易激综合征生活质量量表(IBS-QOL)评分进行评估。治疗后比较两组疗效及安全性。治疗前检测患者的5-HTTLPR基因型。
治疗后及随访时,两组患者IBS-SSS总分均较治疗前降低(P<0.01),且针刺组低于西药组(P<0.01)。治疗后及随访时,两组患者IBS-QOL总分均较治疗前升高(P<0.01),且随访时针刺组高于西药组(P<0.01)。针刺组总有效率为79.2%(122/154),高于西药组的58.4%(45/77)(P<0.01)。两组均未出现严重不良反应。针刺组中LS和SS基因型患者治疗前后IBS-SSS总分差值大于LL基因型患者(P<0.01)。西药组中SS基因型患者治疗前后IBS-SSS总分差值大于LL基因型患者(P<0.01)。针刺组中LS和SS基因型患者治疗前后IBS-SSS总分差值大于西药组中相同基因型患者(P<0.01)。
健脾调神针刺法治疗IBS-D疗效优于匹维溴铵,能有效缓解患者临床症状,提高生活质量,且远期疗效及安全性良好。针刺临床疗效与5-HTTLPR多态性相关,其中LS和SS基因型患者针刺疗效可能更佳。